Hologic, Inc.: Expanding Diagnostic Assay Portfolio For A Competitive Edge! 

Hologic recently announced its financial results for the fourth quarter and fiscal year 2024, showing both strengths and challenges. The total revenue in the fourth quarter was $987.9 million, marking a 4.2% increase compared to the previous year, while organic revenue growth, excluding COVID-related sales, was 5%. Non[1]GAAP earnings per share (EPS) grew by 13.5% to $1.01. For the entire fiscal year, Hologic reported revenue of $4.03 billion with a non-GAAP EPS of $4.08, reflecting 3% growth year-over-year.